{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83d\udc89 One Shot, Lifelong LDL reduction? The Promise of Genomic Cardiology","description":"\ud83e\uddec Could a single infusion replace decades of lipid-lowering therapy? &amp;nbsp; The new NEJM study on VERVE-102 explores in vivo base editing of PCSK9 using CRISPR-inspired adenine base editing technology. In this phase 1 trial, a one-time infusion produced LDL cholesterol reductions up to 62% with durable effects extending beyond 1 year. \u2764\ufe0f &amp;nbsp; This may represent a major shift from chronic pharmacotherapy toward \u201conce-and-done\u201d genomic cardiovascular prevention. &amp;nbsp; The science, safety, clinical implications, and future of gene-editing cardiology on \u201cDr RR Baliga\u2019s Podkast for the Kurious Doc.\u201d \ud83c\udf99\ufe0f\ud83e\udde0 &amp;nbsp; #Cardiology #CRISPR #PCSK9 #PrecisionMedicine #Genomics #LDL #NEJM #MedicalInnovation #PreventiveCardiology #medicalpodca ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41435030\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202335035"}